Biostar Pharmaceutic (BSPM) 4.25 $BSPM Biostar

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biostar Pharmaceutic (BSPM) 4.25 $BSPM

Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended March 31, 2016
PR Newswire - Mon May 23, 3:00PM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the first quarter ended March 31, 2016.
BSPM: 4.25 (-0.07)

Biostar Pharmaceuticals, Inc. Announces Its Annual Results for The Year Ended December 31, 2015
PR Newswire - Thu Apr 14, 3:00PM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the year ended December 31, 2015.
BSPM: 4.25 (-0.07)

Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 22.11 (unch), BSPM: 4.25 (-0.07), ADRO: 14.84 (+0.16), ARWR: 5.86 (-0.10), ARQL: 1.68 (+0.02), AMGN: 174.16 (+2.13), CASI: 1.10 (+0.01), BMY: 76.19 (+1.38), CLBS: 5.70 (+0.16), AAAP: 31.59 (+0.30), CANF: 2.10 (unch), ABUS: 4.17 (+0.08), AZN: 33.84 (-0.30), AVEO: 0.99 (-0.01), ABBV: 66.94 (+0.71), XLRN: 34.40 (+0.48), ARRY: 4.22 (+0.48)

BUYINS.NET: BSPM SqueezeTrigger Price is $2.06. There is $17,430 That Short Sellers Still Need To Cover.
M2 - Fri Feb 05, 9:15AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Biostar Pharmaceuticals Inc (NASDAQ:BSPM) in real time and just received an alert that BSPM is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 8300 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $2.06. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BSPM: 4.25 (-0.07)

Biostar Pharmaceuticals to Effect Reverse Stock Split
PR Newswire - Fri Feb 05, 8:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that its Board of Directors unanimously approved a reverse split of its common stock at a ratio of 1-for-7, with anticipated trading on the post-split basis on NASDAQ commencing at the open of the stock market on February 5, 2016.
BSPM: 4.25 (-0.07)

World Hepatitis B Therapeutics Pipeline Review 2015
M2 - Mon Jan 18, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mxq4b/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hepatitis B Overview - Therapeutics Development - Pipeline Products for Hepatitis B - Overview - Pipeline Products for Hepatitis B - Comparative Analysis - Hepatitis B - Therapeutics under Development by Companies - Hepatitis B - Therapeutics under Investigation by Universities/Institutes - Hepatitis B - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hepatitis B - Products under Development by Companies - Hepatitis B - Products under Investigation by Universities/Institutes - Hepatitis B - Companies Involved in Therapeutics Development- 35 of the 80 Companies Featured - Abivax S.A. - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - Altimmune, Inc. - AltraVax Inc. - Amarna Therapeutics B.V. - Arbutus Biopharma Corporation - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - CaroGen Corporation - CEL-SCI Corporation - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cocrystal Pharma, Inc. - Cytos Biotechnology AG - CyTuVax B.V. - Dong-A ST Co., Ltd. - Dynavax Technologies Corporation - Ensemble Therapeutics Corporation - Enyo Pharma S.A.S. - F. Hoffmann-La Roche Ltd. - GeneCure LLC For more information visit http://www.researchandmarkets.com/research/5m...epatitis_b
DVAX: 15.96 (+0.53), ABUS: 4.17 (+0.08), BSPM: 4.25 (-0.07), CMRX: 4.08 (+0.09), CVM: 0.46 (+0.01), ARWR: 5.86 (-0.10), ASMB: 5.53 (-0.06)

Biostar Pharmaceuticals Inc. Postpones its 2015 Annual Meeting of Shareholders
PR Newswire - Fri Dec 04, 3:00PM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar", "we" or the "Company" , a manufacturer and marketer of pharmaceutical and health supplements to treat a variety of diseases and ailments, headquartered in China, today announced that the Company has decided to postpone the Annual Meeting of Shareholders (the "Annual Meeting" for lack of quorum to conduct business at the Annual Meeting. The Annual Meeting was originally scheduled to be held December 4, 2015, at the Company's offices in Xianyang City, Shaanxi Province, PRC.
BSPM: 4.25 (-0.07)

BiostarPharmaceuticals,Inc. Announces Its Quarterly Results for Three Months Ended September 30, 2015
PR Newswire - Mon Nov 23, 3:00PM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the third quarter ended September 30, 2015.
BSPM: 4.25 (-0.07)

Biostar Pharmaceuticals,Inc. Announces Its Quarterly and Half Year Results for 2015
PR Newswire - Wed Aug 19, 3:30PM CDT
Financial Highlights for the Three and Six Months ended June 30, 2015
BSPM: 4.25 (-0.07)

Hepatitis B - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hepatitis B
M2 - Mon Aug 17, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvqbsr/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatitis B products under development by companies and universities/research institutes based on information Key Topics Covered: - Introduction - Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Abivax S.A. - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - AltraVax Inc. - Amarna Therapeutics B.V. - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - Big DNA Ltd. - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cytos Biotechnology AG - Dynavax Technologies Corporation For more information visit http://www.researchandmarkets.com/research/vv...epatitis_b
DVAX: 15.96 (+0.53), BSPM: 4.25 (-0.07), CMRX: 4.08 (+0.09), ARWR: 5.86 (-0.10), ASMB: 5.53 (-0.06)

Factors Moving Markets: Complementary Research on Biostar, China Gerui, AirMedia, Panera, Amedica
PR Newswire - Tue Apr 21, 8:42AM CDT
Editor Note: For more information about this release, please scroll to bottom.
AMCN: 2.62 (+0.03), BSPM: 4.25 (-0.07), PNRA: 221.38 (+2.06), CHOP: 0.65 (unch), AMDA: 0.84 (+0.01)

Nasdaq stocks posting largest volume increases
AP - Thu Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
IMDZ: 7.63 (-0.04), BSPM: 4.25 (-0.07), TZOO: 10.69 (+0.49), FOMX: 8.01 (-0.51), SLTC: 3.83 (-0.09), BIOD: 0.41 (-0.03), DSKX: 0.67 (-0.18), CLSN: 1.22 (-0.01), DOVR: 8.43 (+0.03), MRCC: 15.18 (-0.58), VGGL: 0.42 (unch), TGLS: 10.88 (-0.17), INPH: 0.04 (unch), CHNR: 1.73 (-0.02)

Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results
PR Newswire - Wed Apr 15, 3:30PM CDT
Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar", "we" or the "Company" , a manufacturer and marketer of pharmaceutical and health supplements to treat a variety of diseases and ailments, headquartered in China, today announced its results of operations for the full year and the quarter ended December 31, 2014.
BSPM: 4.25 (-0.07)

Biostar Pharmaceuticals, Inc. Announces Signing of Joint Research and Development Agreement with Northwest University for Further Development of Danshensu Yibingzhi (IDHP), a Class One Drug for Treatment of Cardiovascular Diseases
PR Newswire - Thu Jan 08, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on December 29, 2014, the Company signed a joint research and development agreement with Northwest University, one of China's leading comprehensive universities located in Xi'an city, Shaanxi Province, for further development of Danshensu Yibingzhi (IDHP), a Class One drug for treatment of cardiovascular diseases to further research and development efforts in connection with Danshensu Yibingzhi (IDHP).
BSPM: 4.25 (-0.07)

OTC Daily Alert Stock Watch - Biostar Pharmaceuticals, Inc., (NASDAQ: BSPM)
WorldStockWire - Mon Dec 29, 3:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
BSPM: 4.25 (-0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 168

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 99

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 183

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 149

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 150

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 46

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading

Top 5 Most Recently Viewed Articles

Chuyuan Group's Transformative Journey Towards Sustainable Success

Updated Category News Views 226

Chuyuan Group's Path to Sustainability and Growth In recent years, Chuyuan Group has significantly transformed its operations, embracing high-quality development in response to the evolving regulatory landscape. As the industry landscape changes, companies like Chuyuan must adapt to remain competitive and environmentally responsible. Understanding the Shift: Old Yang and...

Continue Reading
Adani Bonds Face Downgrade Risk Amid U.S. Bribery Scandal

Updated Category News Views 355

Fitch Ratings Puts Adani Group Bonds on Negative Watch In a significant move, Fitch Ratings has placed bonds from various units of the Adani Group on a watchlist for potential downgrades. This action follows serious allegations against the conglomerate's top executives, who are facing U.S. charges related to bribery and fraud. Implications of the Watch Status Fitch's...

Continue Reading
Investigation of Arbor Realty Trust: What Investors Should Know

Updated Category News Views 81

Understanding the Investigation of Arbor Realty Trust Faruqi & Faruqi, LLP, a well-known national securities law firm, is currently looking into claims related to Arbor Realty Trust, Inc. (NYSE: ABR). Investors who have suffered losses exceeding $100,000 while investing in Arbor are encouraged to get in touch for more information and support. Who Should Reach Out to...

Continue Reading
Qualcomm's Strategic Move: Potential Intel Acquisition Talks

Updated Category News Views 185

Qualcomm's Interest in Intel's Assets Recently, Qualcomm has made headlines by showing interest in buying parts of Intel. This move seems to be a strategic effort by Qualcomm to strengthen its presence in the competitive technology market, especially within the chip manufacturing sector. Shifting Market Dynamics Intel, a leader in chip production, is currently facing...

Continue Reading
Refined Energy Corp Expands Partnership with Eagle Plains Resources

Updated Category News Views 113

Refined Energy Corp Strengthens Its Partnership Refined Energy Corp announces an important amendment to its agreement with Eagle Plains Resources Ltd. The key focus of this amendment is to enhance their collaboration on the Dufferin Project, a project located in Canada's Athabasca Basin, known for its rich mineral deposits. Details of the Amended Agreement In a recent...

Continue Reading